Loading…
Axsome Therapeutics, Inc. is projected to rise to $310.23 by 2027, a +32% move from its current price of $234.52. AXSM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $230.13 | $234.71 | $239.39 | +0.08% |
| May 30 | $228.45 | $234.91 | $241.56 | +0.17% |
| May 31 | $227.21 | $235.10 | $243.28 | +0.25% |
| Jun 1 | $226.20 | $235.30 | $244.77 | +0.33% |
| Jun 2 | $225.33 | $235.49 | $246.12 | +0.42% |
| Jun 3 | $224.57 | $235.69 | $247.36 | +0.50% |
| Jun 4 | $223.89 | $235.89 | $248.53 | +0.58% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $223.89 | $235.89 | $248.53 | +0.58% |
| Week 2 | $220.38 | $237.26 | $255.44 | +1.17% |
| Week 3 | $218.01 | $238.64 | $261.22 | +1.76% |
| Week 4 | $216.24 | $240.03 | $266.45 | +2.35% |
| Week 5 | $214.83 | $241.43 | $271.32 | +2.95% |
| Week 6 | $213.69 | $242.84 | $275.96 | +3.55% |
| Week 7 | $212.74 | $244.25 | $280.43 | +4.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Axsome Therapeutics, Inc. is a biopharmaceutical company that develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Its commercial product portfolio includes Auvelity (dextromethorphan-bupropion), Sunosi (solriamfetol), and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational NMDA receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as Phase II trials for smoking cessation. AXS-12 (reboxetine), AXS-14 (esreboxetine), and Solriamfetol are other programs in development with various CNS indications, and there is a research collaboration with Duke University evaluating AXS-05 in smoking cessation.
The company was incorporated in 2012 and is based in New York, New York.
AXSM trades at $235.97, with a market cap of $12.14B, and is ranked 804.
The 30-day range is $205.61 to $270.82, reflecting the near-term trading band.
The long-term price outlook, as shown by the year-by-year forecast, is bullish with rising averages and ROIs. The 2026 avg is $235.97 (ROI 0), and the trajectory extends to a 2050 avg of $3,594.79 (ROI 1,423.4) with bullish sentiment along the way.
A major floor 34.3% below — a decisive break under it would weaken the trend.
The nearest floor, 22.1% below — buyers have tended to step in here.
Price is pressing into resistance (0.6% away) — a breakout level to watch.
A major ceiling 15.5% above — clearing it would confirm fresh momentum.
Key AXSM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AXSM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $233.79 | Buy | $233.35 | Buy |
| MA 10 | $231.83 | Buy | $230.16 | Buy |
| MA 20 | $223.20 | Buy | $221.57 | Buy |
| MA 50 | $193.09 | Buy | $202.28 | Buy |
| MA 100 | $184.28 | Buy | $185.49 | Buy |
| MA 200 | $158.01 | Buy | $164.69 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 71.02 | Sell |
| Stoch RSI (14) | 26.37 | Neutral |
| CCI (20) | 86.10 | Neutral |
| Williams %R (14) | -7.44 | Info |
| MACD (12,26,9) | -0.47 | Sell |
| ROC (12) | 7.88 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 92.56 | Sell |
| TRIX (15) | 0.94 | Buy |
| Awesome (5,34) | 26.73 | Buy |
| Ultimate (7,14,28) | 72.53 | Sell |
| Momentum (10) | 10.49 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 236.37 | Sell |
| ADX (14) | 40.13 | Buy |
| ATR (14) | 3.42 | Info |
The 30-day technical picture is bullish in sentiment.
RSI14 sits at 70, with the stock trading above the 50-day and 200-day indicators. The SMA50 is $190.00 and the SMA200 is $156.71, suggesting a constructive near-term trend. Support is at $178.33 and resistance at $235.97, placing the current price near the upper end of a defined range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $154.12 | $234.52 | $317.44 | 0% | Neutral | |
| $252.66 | $310.23 | $399.26 | +32% | Bullish | |
| $285.29 | $357.01 | $471.99 | +52% | Bullish | |
| $327.01 | $415.74 | $561.54 | +77% | Bullish | |
| $390.52 | $503.45 | $692.54 | +115% | Bullish | |
| $487.54 | $636.53 | $889.77 | +171% | Bullish | |
| $563.76 | $744.72 | $1,056.22 | +218% | Bullish | |
| $598.33 | $799.11 | $1,148.44 | +241% | Bullish | |
| $655.44 | $884.51 | $1,286.80 | +277% | Bullish | |
| $701.06 | $955.47 | $1,405.96 | +307% | Bullish | |
| $1,242.13 | $1,769.62 | $2,732.62 | +655% | Bullish | |
| $2,255.29 | $3,459.98 | $5,739.04 | +13.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $154.12 | $234.52 | $275.21 | +0.00% |
| June 2026 | $209.55 | $244.62 | $291.23 | +4.31% |
| July 2026 | $215.39 | $252.96 | $304.14 | +3.41% |
| August 2026 | $213.73 | $252.19 | $305.53 | -0.30% |
| September 2026 | $213.54 | $252.95 | $308.35 | +0.30% |
| October 2026 | $218.08 | $259.25 | $317.81 | +2.49% |
| November 2026 | $217.89 | $259.84 | $320.10 | +0.23% |
| December 2026 | $214.43 | $256.49 | $317.44 | -1.29% |
Click any year to see its month-by-month AXSM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AXSM to range from $154.12 to $317.44 through 2026. The $234.52 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The AXSM price prediction for 2027 points to an average of $310.23 (low $252.66, high $399.26) — a potential gain of +32% on today's $234.52. Buyers look set to stay in control over this stretch.
In 2028, AXSM is projected to trade between $285.29 and $471.99, averaging $357.01 — a potential gain of +52% from today's $234.52. That is up +15% on the projected 2027 average. Momentum favours further upside here.
Axsome Therapeutics, Inc.'s 2029 outlook centres on $415.74, within a $327.01 to $561.54 range. That is up +16% on the projected 2028 average. That marks a +77% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, AXSM could reach as high as $692.54, with a base case around $503.45 and support toward $390.52 — roughly +115% from $234.52. Momentum favours further upside here.
Expect AXSM to range from $487.54 to $889.77 through 2031. The $636.53 average target implies a +171% move from current prices. That is up +26% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The AXSM price prediction for 2032 points to an average of $744.72 (low $563.76, high $1,056.22) — a potential gain of +218% on today's $234.52. Momentum favours further upside here.
In 2033, AXSM is projected to trade between $598.33 and $1,148.44, averaging $799.11 — a potential gain of +241% from today's $234.52. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Axsome Therapeutics, Inc.'s 2034 outlook centres on $884.51, within a $655.44 to $1,286.80 range. That is up +11% on the projected 2033 average. That marks a +277% change versus current levels. Momentum favours further upside here.
By 2035, AXSM could reach as high as $1,405.96, with a base case around $955.47 and support toward $701.06 — roughly +307% from $234.52. Buyers look set to stay in control over this stretch.
Expect AXSM to range from $1,242.13 to $2,732.62 through 2040. The $1,769.62 average target implies a +655% move from current prices. That is up +85% on the projected 2035 average. Momentum favours further upside here.
The AXSM price prediction for 2050 points to an average of $3,459.98 (low $2,255.29, high $5,739.04) — a potential gain of +13.8x on today's $234.52. Buyers look set to stay in control over this stretch.
Investing $1,000 in AXSM today (≈ 4.264029 AXSM) could be worth
$14,753.45
+$13,753.45 (+1375%) by 2050 · US Dollar
Based on the average projected AXSM price of $3,459.98 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AXSMwould be worth at today's price.
$1,000 invested in AXSM on May 27, 2025 (≈ 9.617234 AXSM) would be worth
$2,255.43
+$1,255.43 (+125.5%) today · 2.26× · US Dollar
Based on a AXSM entry price of $103.98 vs. today's $234.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $230.62 | $1,016.91 | +1.7% |
| 1 month ago | $187.4 | $1,251.44 | +25.1% |
| 3 months ago | $163.19 | $1,437.1 | +43.7% |
| 6 months ago | $151.5 | $1,547.99 | +54.8% |
| 1 year ago | $103.98 | $2,255.43 | +125.5% |
| All time (5.0y) ago | $61.7 | $3,800.97 | +280.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AXSM forecast.
Our base-case forecast reaches $470.00 around 2030.
Implied market cap at $470.00: $24.19B
The multi-year forecast shows a persistent bullish tilt across the later years. From 2027 onward, the average price climbs from $316.27 (ROI 34) to $3,594.79 by 2050 (ROI 1,423.4), with sentiment remaining BULLISH.
Key milestones include 2028 with an avg of $361.28 (ROI 53.1) and 2029 with an avg of $422.45 (ROI 79), progressing to 2030 with an avg of $517.89 (ROI 119.5) and 2035 with an avg of $983.76 (ROI 316.9). The forecast reaches 2040 with an avg of $1,819.91 (ROI 671.2) and culminates in 2050 at $3,594.79 (ROI 1,423.4). These figures imply a strong longer-term upside but are not guarantees and should be viewed as estimates within market uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $398.75, an avg of $517.89, and a max of $719.17, with an ROI of 119.5 and a BULLISH sentiment.
The forecast shows bullish sentiment across multiple years with rising averages and ROIs, including 2027 avg $316.27 (ROI 34) through 2050 avg $3,594.79 (ROI 1,423.4). These estimates imply upside potential but are not guarantees.
Yes. The 2035 avg is $983.76 and the 2040 min is $1,259.21, with 2040 avg $1,819.91 and max $2,851.90, indicating the potential to exceed $1,000 by 2040.
Current price is $235.97 and market cap is $12.14B.
The 30-day technical picture is bullish; RSI14 is 70, SMA50 is $190.00, SMA200 is $156.71, with support at $178.33 and resistance at $235.97. The 30-day range runs from $205.61 to $270.82.
Axsome Therapeutics, Inc. Community Discussion
0Share your Axsome Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.